All News

What should you use as a second-line biologic in PsA patients? In pts who discontinued TNFi, switching to a different MOA led to comparable or better outcomes vs. cycling through another TNFi. Abs#1600 @RheumNow #ACR22 https://t.co/9MZPSHD7we

Spangler et al. No increased risk of MI or stroke in denosumab vs zoledronate in 170,000 patients from Optum/MarketScan. @RheumNow #ACR22 Abstr#0575 https://t.co/5fho4WBsIG https://t.co/PNCI4xJ38u

Myocardial Infarction and Stroke Risks Among Patients Who Initiated Treatment w…

Does curcumin help maintain drug-free remission RA? Answer is No Single center RCT Curcumin vs PBO w/ MTX withdrawal = flare-free survival = median time to flare (219 d vs. 214 d) Serum curcuminoid levels not asso w/ flares https://t.co/3U6W0Iuqrq Abs#1587 #ACR22 @Rheumnow https://t.co/GwAsY7OKTX

http://bit.ly/3URYakx

Metabolic disorders +diet patterns PsA 👉71.9% obese 👉metabolic synd 46.9% 👉dyslipid 41.9% 👉 HTN 37.5% Diet patterns assoc Dx activity ⬇️sugar⬇️fatigue⬇️PSAID score ⬆️whole fruit ⬇️SJC ⬆️unsat fats ⬆️enthesitis DIPSA -Med/DASH diet PsA ongoing #ACR22 @RheumNow Abst1007 https://t.co/cbggEw6IZp

TOFA and MTX: which one to withdraw first? RCT in 100+ RA pts in remission after 1 yr, 1 yr follow-up Withdraw MTX grp: Remission 30% LDA 40% Withdraw TOFA grp: Remission 50% LDA 65% diff NS small sample 8 SAEs, 72% recovery https://t.co/tMnet32TWF Abs#1586 #ACR22 @Rheumnow https://t.co/PWnkWYdlGk

Sustained Remission Following the Discontinuation of Tofacitinib in Patients wi…

"Do patients care/look for telehealth in 2022?" Ben Nowell states patients have supported telehealth for access, convenience, and affordability (gas, parking, etc.) 60% of pts still like these visits. Are you doing telemed #ACR22? @RheumNow https://t.co/5fAHsp2kBD

I see more and more studies on #ArtificialIntelligence using social media posts! I think this is an extension/future of qualitative studies 40% of posts associated with negative sentiment toward #pregnancy #SLE fear and sadness! #ACR22 abst#1335 @rheumnow https://t.co/qwk6pYeeXR

Artificial Intelligence–enabled Sentiment Analysis of Public Attitude Toward Pr…

Cycling to 2nd after 1st line TNFi in AxSpA provides ◦ Limited benefits to pts ◦ Few pts showed clinically meaningful improvement in disease severity after 6 months ◦ Less than 25% pts remained on therapy after 2 years Mease P Abs1499 https://t.co/0Txs82KRbx #ACR22 @RheumNow https://t.co/xJiIWe9yDp

The Impact of Cycling Among Tumor Necrosis Factor Inhibitors on Disease Control…

Devauchelle-Pensec et al. SEMAPHORE RCT- tocilizumab in refractory PMR. TCZ treated GC dependent patients - better disease activity, reduced GC, less flare, more frequent GC-free remission @RheumNow #ACR22 Abstr#1106 https://t.co/UevgjF8di5 https://t.co/GmXqasNscp

Effect of Tocilizumab on Disease Activity in Patients with Active Polymyalgia R…

RheumNow’s expanded coverage of the #ACR22 Annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its Faculty

What to do next? Dazodalibep Rx in bDMARDs IR #RA pts. Dazo is a novel CD40 ligand antagonist Phase II RCT. N=78, multi dose phase II RCT. All doses improved DAS28. Dosing interval may be prolonged over time. Awaiting phase 3. Abst#2008 #ACR22 @RheumNow https://t.co/IrzflycKZp

#abst2132 #acr22 @rheumnow safety of Deucravacitinib Ph2PsA&ph3PSO trial: no Δ from BL in hematology, chemistry, or lipid labs. JAK 1/2/3 Effects on hem, hepatic, CPK, and cholesterol lab parameters not observed over 16 wks of DEUC at doses up to 12 mg QD & in combo w/csDMARDs. https://t.co/bjGEYp4GcJ

Hoffmann-Vold et al. SSc ILD frequently progresses even in long-standing SSc. Not just a disease of early SSc! @RheumNow #ACR22 Abstr#1536 https://t.co/nKiY2xFxfk https://t.co/W7SDm6QFpQ

Progressive Interstitial Lung Disease Is Frequent Also in Late Disease Stages i…

Ghaffar et al. Chronic abdominal periaortitis. Imaging improved in only 57% and resolved in 9%. Incident aneurysms rare 8%. Older age and secondary cause assoc greater likelyhood improvement, smokers 2 times less likely. @RheumNow #ACR22 Abstr#1576 https://t.co/jS9djx3ZtU https://t.co/OFW2Jk7gGW

Clinical Presentation and Outcome of Patients with Chronic Abdominal Periaortit…

13S150. Draft ACR/EULAR APLS Classif Crit #ACR22 Entry: Clinical & +aPL w/in 3 yr Then: Additive crit -Don't count other cause Clinical Domains: Macrovasc VTE, Macrovasc AT, Microvasc, Obst, Cardiac, Hematology Lab: +LA, aCL/B2GP IgM/IgG/titer Total: 3+ clin, 3+ lab @RheumNow https://t.co/YeKW0orjZC

⬆️ serum anti-CCP3 Ab, absence IA 👉 StopRA trial - ironically stopped🛑 ❌ hydroxychloroquine not superior to PBO in preventing/ delaying IA 👉rate of conversion to RA in CCP3+ve ~35% @ 3yrs #ACR22 @RheumNow Abst#1604

“As long as you are practicing rheumatology, your legal risk is low.” - @greerdonley, law professor, on how rheumatologists should not let fear of legal consequences interfere w/practicing high quality evidenced based medicine for our patients #ReproductiveRheum #ACR22 @rheumnow

Makol @AshimaMakol et al. Multimorbidity in SSc . SSc higher burden multimorbidity at diagnosis and higher risk of developing multimorbidity over time @RheumNow #ACR22 Abstr#1190 https://t.co/VopFI6U5G5 https://t.co/hKKPC7v8EN

Multimorbidity in Systemic Sclerosis: Burden and Trends in Prevalence from an I…

CorEVITAS Abs 1499 #ACRbest #ACR22 cycling to a second line TNFi provides limited benefits to pts with AxSpA who discontinued a first line TNFi. @RheumNow https://t.co/fKDa5kPfXN https://t.co/CtMCj2Ihgc

The Impact of Cycling Among Tumor Necrosis Factor Inhibitors on Disease Control…

Mazareeb et al. von Willebrand Factor in systemic vasculitis. Increased in active vasculitis compared to remission and HCs. Correlates disease activity. Not affected by IL6i. @RheumNow #ACR22 Abstr#1573 https://t.co/uJAFHQpOlu https://t.co/PNX0puOeCn

Von – Willebrand Factor, a Possible Marker for Disease Activity in Vasculitis -…

Topics

All News

Do you get our email newsletter?